...物,支架上局部释放的药物能有效降低支架内再狭窄(in-stent restenosis,ISR)和靶血管重建(target vessel revascularization, TVR)率。目前,绝大部分患者(90%左右)在球囊扩张后均需要支架植入。
基于4个网页-相关网页
...上局部释放的药物能有效降低支架内再狭窄(in-stent restenosis,ISR)和靶血管重建(target vessel revascularization, TVR)率。目前,绝大部分患者(90%左右)在球囊扩张后均需要支架植入。
基于2个网页-相关网页
和靶血管血运重建 Target Vessel Revascularization ; TVR
结果对47例患者进行随访,病死率、靶血管重建率和主要心脏事件发生率分别为2.1%、2.1%和6.4%。
ResultsFor follow-up 47 patients, the mortality, target vessel revascularization ratio and major adverse cardiac events were 2.1%, 2.1%, 6.4%.
主要终点为主要不良心血管事件(MACE),定义为死亡,心肌梗塞(MI),休克和靶血管血运重建(TVR)。
The primary end point used was major adverse cardiac events (MACE), defined as death, myocardial infarction (MI), stroke and target vessel revascularization (TVR).
30天和一年的住院期间,其主要结局是缓慢流动/无复流现象(SF-NR)的发生,临床终点包括死亡、心肌梗死(MI)、靶病变血管血运重建术(TVR)和主要心脏不良事件(MACE)。
The primary outcome was the occurrence of SF-NR Clinical endpoints included death, MI, target vessel revascularization (TVR), and MACE during the hospitalization period, 30 days and at 1 year.
应用推荐